Venous Thromboembolism Market Report 2026

The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.53 billion in 2025 to $2.63 billion in 2026 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to increasing incidence of venous thromboembolism, aging population growth, rising prevalence of sedentary lifestyles, improved clinical awareness of vte risks, expansion of hospital-based thrombotic care.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing adoption of personalized anticoagulant therapy, growing demand for minimally invasive treatment options, expansion of outpatient vte care models, rising investment in advanced diagnostic tools, increasing focus on preventive thrombosis management. Major trends in the forecast period include increasing adoption of novel oral anticoagulants, rising use of mechanical thrombectomy devices, growing focus on early diagnosis and risk stratification, expansion of home-based vte management programs, improved monitoring of anticoagulant therapy.

The expansion of healthcare infrastructure is expected to drive growth in the venous thromboembolism market in the coming years. The healthcare industry encompasses the integration of sectors within the economy that provide products and services for treating, preventing, rehabilitating, and offering palliative care for patients. Growth in the healthcare industry supports the development of institutional infrastructure, policies, practices, and educational programs necessary to implement VTE prevention protocols effectively. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States rose to 6,129 from 6,093 in 2022. Therefore, the expansion of the healthcare industry is fueling growth in the venous thromboembolism market.

The increasing number of orthopedic procedures is also expected to propel growth in the venous thromboembolism market. Orthopedic procedures are surgical interventions used to treat conditions affecting the spine and joints and to correct skeletal deformities. Procedures such as total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) carry a high risk of VTE, which has led to increased adoption of compression devices for DVT prophylaxis. Compression devices help prevent blood clots from forming in the deep veins of the legs, reducing the risk of venous thromboembolism. For instance, in February 2023, research published by the National Library of Medicine, a US-based biomedical library, projected that total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures will increase to 719,364 and 1,222,988, respectively, by 2040. Furthermore, TKAs are expected to total 2,917,959 by 2060, while THAs are projected to reach 1,982,099. Therefore, the rising number of orthopedic procedures is driving the growth of the venous thromboembolism market.

Major companies operating in the venous thromboembolism (VTE) market are focusing on integrating advanced vascular-access sheath technologies, such as laser-cut hypotube sheaths, to improve procedural efficiency, safety, and control. Laser-cut hypotube sheath technology uses a thin-walled metal tube precisely cut with a laser to create a sheath that is flexible yet structurally supportive, allowing smooth navigation through blood vessels, stable catheter delivery, and better hemostasis control during interventions. For instance, in January 2025, Penumbra Inc., a US-based medical device manufacturer, launched the Element Vascular Access System, a laser-cut hypotube sheath designed specifically for venous thromboembolism procedures. The system features the HemoLock dual-valve for precise hemostasis control, an atraumatic tip design, and 17 F MaxID sizing for smooth delivery and compatibility with large-bore thrombectomy catheters. Element enhances procedure efficiency, device trackability, and physician control, potentially improving safety and treatment outcomes in VTE interventions.

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi‑Aventis LLC, Bristol‑Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Co Ltd, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Portola Pharmaceuticals Inc, Viatris Inc, AstraZeneca PLC, Medtronic plc, Boston Scientific Corporation, Stryker Corporation, Abbott Laboratories, AngioDynamics Inc, Terumo Corporation.

North America was the largest region in the venous thromboembolism market in 2025. The regions covered in the venous thromboembolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the venous thromboembolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the venous thromboembolism market by increasing costs of imported anticoagulant drugs, diagnostic imaging equipment, thrombectomy devices, and hospital consumables used across vte treatment pathways. Healthcare providers in North America and Europe are most affected due to reliance on imported pharmaceuticals and medical devices, while Asia-Pacific faces pricing pressure on advanced therapeutics. These tariffs are contributing to higher treatment costs and procurement challenges for hospitals and specialty centers. However, they are also encouraging domestic pharmaceutical manufacturing, local medical device production, and improved regional supply chain resilience for critical vte treatment products.

The venous thromboembolism market research report is one of a series of new reports that provides venous thromboembolism market statistics, including venous thromboembolism industry global market size, regional shares, competitors with a venous thromboembolism market share, detailed venous thromboembolism market segments, market trends and opportunities, and any further data you may need to thrive in the venous thromboembolism industry. This venous thromboembolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Venous thromboembolism (VTE) is a medical condition marked by the formation of blood clots within the veins, which can result in serious or potentially life-threatening complications. Common symptoms of VTE include leg pain and swelling, rapid breathing, chest pain, and more. Various treatment approaches, including anticoagulant medications, medical devices, and thrombolytic therapy, are used to manage VTE.

The main types of venous thromboembolism include deep vein thrombosis, pulmonary embolism, and others. Deep vein thrombosis (DVT) is a condition in which blood clots form in the deep veins of the body. Treatments for DVT include anticoagulant medications, mechanical devices, thrombolytic therapy, and other interventions, and are used by end users such as hospitals, home care providers, specialty centers, and others.

The venous thromboembolism market consists of revenues earned by entities by providing services such as surgical assistance and thrombolytic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous thromboembolism market also includes the sales of heparin, apixaban, dabigatran, rivaroxaban, edoxaban and warfarin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.